Australia's EchoIQ gains most in over 2-months on deal with U.S. hospital firm Mayo Clinic
23/03/2026 23:29
** Shares of Australia's EchoIQ EIQ.AX rise as much as 17.1% to A$0.72; on track to record their biggest intraday pct gain since January 22 ** Stock at its highest level since March 12 ** Medical tech firm announces agreement with U.S hospital firm Mayo Clinic in preparation for potential FDA clearance of EchoSolv HF ** EchoSolv HF is AI-based clinical decision-support software designed to help detect heart failure using echocardiography data ** Adds agreement enables Mayo Clinic to resell and distribute EchoSolv HF following FDA clearance ** Stock has risen 169.2% pct this year, including session moves (Reporting by Roshan Thomas in Bengaluru) ((Roshan.Thomas@thomsonreuters.com;))
Recent news on EchoIQ
See all newsAustralia's EchoIQ gains most in nearly 3 months after FDA update
Brief: EchoIQ Says FDA Raises No Concerns About Echosolv HF Technology Or Core Functionality
Australia's EchoIQ heads for worst week in seven years after US FDA setback
Australia's Echo IQ logs worst day in seven years after FDA setback
Brief: EchoIQ Requests Trading Halt